Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

HHS Secretary Robert F. Kennedy Jr.’s actions in recent months have raised concerns that he is taking a heavy-handed and ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

At a satellite kickoff event to the annual BIO meeting, investment bankers and VCs gave reasons for optimism amid a ‘volatile ...

The program will bring together experts from across the FDA for a team-based review, rather than having an application move ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...